Evidence map›Paper›PMID 23062075›Full record

ArticleBMC complementary and alternative medicine2012

Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.

Suwit Duangmano, Phorntip Sae-Lim, Apichart Suksamrarn, Frederick E Domann, Pimpicha Patmasiriwat

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 86 citations in OpenAlex.

  1. Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Pharmacological and Clinical Efficacy ofMolecules (Basel, Switzerland) · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Screening a Prognosis-Related Target Gene in Patients with HER-2-Positive Breast Cancer by Bioinformatics Analysis.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Suwit DuangmanoSchool of Allied Health Science and Public Health, Walailak University, Bangkok, Thailand.
Phorntip Sae-Lim
Apichart Suksamrarn
Frederick E Domann
Pimpicha Patmasiriwat
Ramkhamhaeng University · THMahidol University · THUniversity of Iowa · USWalailak University · TH

Funding

Epigenetic factors governing SOD2 gene expressionR01CA073612 · NCI · UNIVERSITY OF IOWA · PI DOMANN, FREDERICK E · 2003 to 2007
$1.3M
Molecular Species Responsible for Tumor Supressive Effect of MnSODR01CA115438 · NCI · UNIVERSITY OF IOWA · PI DOMANN, FREDERICK E · 2007 to 2011
$1.2M
NCI NIH HHS R01 CA115438NCI NIH HHS R01CA73612
6 · The paper itself

Abstract

backgroundCucurbitacin B, an oxygenated tetracyclic triterpenoid compound extracted from the Thai medicinal plant Trichosanthes cucumerina L., has been reported to have several biological activities including anti-inflammatory, antimicrobial and anticancer. Cucurbitacin B is great of interest because of its biological activity. This agent inhibits growth of various types of human cancer cells lines.

methodsIn this study, we explored the novel molecular response of cucurbitacin B in human breast cancer cells, MCF-7 and MDA-MB-231. The growth inhibitory effect of cucurbitacin B on breast cancer cells was assessed by MTT assay. The effects of cucurbitacin B on microtubules morphological structure and tubulin polymerization were analyzed using immunofluorescence technique and tubulin polymerization assay kit, respectively. Proteomic analysis was used to identify the target-specific proteins that involved in cucurbitacin B treatment. Some of the differentially expressed genes and protein products were validated by real-time RT-PCR and western blot analysis. Cell cycle distributions and apoptosis were investigated using flow cytometry.

resultsCucurbitacin B exhibited strong antiproliferative effects against breast cancer cells in a dose-dependent manner. We show that cucurbitacin B prominently alters the cytoskeletal network of breast cancer cells, inducing rapid morphologic changes and improper polymerization of the microtubule network. Moreover, the results of 2D-PAGE, real-time RT-PCR, and western blot analysis revealed that the expression of nucleophosmin/B23 and c-Myc decreased markedly after cucurbitacin B treatment. Immunofluorescence microscopy showed that cucurbitacin B induced translocation of nucleophosmin/B23 from the nucleolus to nucleoplasm. Treatment with cucurbitacin B resulted in cell cycle arrest at G2/M phase and the enhancement of apoptosis.

conclusionsOur findings suggest that cucurbitacin B may inhibit the proliferation of human breast cancer cells through disruption of the microtubule network and down-regulation of c-Myc and nucleophosmin/B23 as well as the perturbation in nucleophosmin/B23 trafficking from the nucleolus to nucleoplasm, resulting in G2/M arrest.

Indexed as

PhytotherapyAntineoplastic Agents, PhytogenicApoptosisBreast NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationDose-Response Relationship, DrugFemaleHumansMicrotubulesNuclear ProteinsNucleophosminPlant ExtractsPolymerizationProtein TransportAntineoplastic Agents, Phytogeniccucurbitacin BMYC protein, humanNPM1 protein, humanNuclear ProteinsNucleophosminPlant ExtractsProto-Oncogene Proteins c-mycTriterpenes

Identifiers

PMID23062075
PMCPMC3527297
OpenAlexW2022961915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.